Ascentage Pharma presents positive results from phase I study of Bcl-2 inhibitor lisaftoclax (APG-2575) in Chinese patients with r/r NHL at EHA 2022 Congress
By, Admin1 min read
Share
Ascentage Pharma, a global biopharmaceutical company, announced that it has released results from a phase I study of the company
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
